Polymyxin B

Phase 3Small molecule

MMahidol University

Polymyxin B is one of 111 small molecule programs targeting Bacterial Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial PneumoniaActive, not recruiting

PneumoniaActive, not recruiting

Renal InsufficiencyActive, not recruiting

Bacterial PneumoniaPhase 3

Active, not recruiting

PneumoniaPhase 1

Active, not recruiting

Renal InsufficiencyPhase 1

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Polymyxin B

MMahidol University

Phase 3

1 2

Jakafi

Incyte

Preclinical

1 3

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 4

Advil

KKenvue Brands

Preclinical

2 5

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 6

Alka-Seltzer

AAbbott

Preclinical

1 7

Tylenol

KKenvue Brands

Preclinical

1 8

Tagamet

DDT MedTech, LLC

Preclinical

1 9

Prograf

VVeloxis Pharmaceuticals

Preclinical

1 10

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Infections

NCT06595979

Q1 2028

Phase 3Not yet recruiting

Bacterial Pneumonia

NCT07326540

Clinical

Trials by Indication[1]

Infections2 trials

Intraventricular Administration of Intracranial Infections Caused by （Carbapenem-resistant Gram-negative Bacilli）CRGNB

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT06595979·222 enrolled

Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria

Unknown status·MMahidol University·Phase 4·NCT02328183·100 enrolled

Pneumonia1 trial

The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae

Unknown status·SShanghai 10th People's Hospital·Phase 1·NCT03950544·80 enrolled

Randomized1 trial

Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria

Withdrawn·TTan Tock Seng Hospital·Phase 2/3·NCT02134106

Renal insufficiency1 trial

A Pharmacokinetic Study of Polymyxin B in Healthy Subjects and Subjects With Renal Insufficiency

Completed·TTTY Biopharm·Phase 1·NCT05359627·22 enrolled

Bacterial Pneumonia1 trial

Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Not yet recruiting·BBioVersys AG·Phase 3·NCT07326540·248 enrolled

1 more indication

Critically Ill Patients1 trial

Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens

Unknown status·UUniversity of Puerto Rico·Phase 3·NCT03159078·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Polymyxin B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polymyxin B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Polymyxin B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mahidol University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMahidol University

Polymyxin B

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Trials by Indication[1]

Infections2 trials

Pneumonia1 trial

Randomized1 trial

Renal insufficiency1 trial

Bacterial Pneumonia1 trial

Critically Ill Patients1 trial

References

Drug Info

Quick Facts

Related News